Hyung Soon Park, PhD, is the Chief Scientific Officer (CSO) and director of the R&D Center at Glaceum, with over 25 years of experience in the field of drug discovery and development. Throughout his doctoral studies at Seoul National University and postdoctoral studies at Yale University, Dr. Park specialized in studying the molecular interactions between proteins and small molecules to identify potential drug candidates for a diverse set of diseases. Before joining Glaceum, Dr. Park was CEO of Probiond, a company he founded to develop chemical screening systems for the discovery of drug candidates and biomarkers, and he was CSO for Diatech Korea and the vice president for NosVet. He has extensive experience in the field, ranging from drug discovery, preclinical assays and clinical development, up to commercialization. At Glaceum, Dr. Park is responsible for the development of two clinical-stage compounds for the treatment of metabolic, inflammatory and neurodegenerative diseases.
Evaluating the Ability of HSG4112, An Anti-obesity Drug Candidate, to Protect Dopamine-producing Neurons Against Mitochondrial Dysfunction